- Home
- AMS vs VYNE Comparison
AMS vs VYNE Comparison
Compare AMS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- VYNE
- Stock Information
- Founded
- AMS 1980
- VYNE 2003
- Country
- AMS United States
- VYNE United States
- Employees
- AMS N/A
- VYNE N/A
- Industry
- AMS Medical Specialities
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- VYNE Health Care
- Exchange
- AMS Nasdaq
- VYNE Nasdaq
- Market Cap
- AMS 18.3M
- VYNE 16.0M
- IPO Year
- AMS N/A
- VYNE 2018
- Fundamental
- Price
- AMS $2.35
- VYNE $1.42
- Analyst Decision
- AMS
- VYNE Strong Buy
- Analyst Count
- AMS 0
- VYNE 2
- Target Price
- AMS N/A
- VYNE $6.25
- AVG Volume (30 Days)
- AMS 13.6K
- VYNE 964.9K
- Earning Date
- AMS 08-13-2025
- VYNE 08-13-2025
- Dividend Yield
- AMS N/A
- VYNE N/A
- EPS Growth
- AMS 151.01
- VYNE N/A
- EPS
- AMS 0.21
- VYNE N/A
- Revenue
- AMS $29,236,000.00
- VYNE $605,000.00
- Revenue This Year
- AMS $23.63
- VYNE $42.51
- Revenue Next Year
- AMS N/A
- VYNE N/A
- P/E Ratio
- AMS $11.30
- VYNE N/A
- Revenue Growth
- AMS 35.25
- VYNE 43.03
- 52 Week Low
- AMS $2.30
- VYNE $0.85
- 52 Week High
- AMS $4.60
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- AMS 46.47
- VYNE 77.62
- Support Level
- AMS $2.30
- VYNE $0.85
- Resistance Level
- AMS $2.50
- VYNE $0.97
- Average True Range (ATR)
- AMS 0.12
- VYNE 0.13
- MACD
- AMS 0.01
- VYNE 0.08
- Stochastic Oscillator
- AMS 32.36
- VYNE 85.56
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.